benzoxazoles has been researched along with Schizophrenia in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (71.43) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chattopadhyay, A; Frey, S; Green, G; Harkness, A; McDermott, A; Yates, A | 1 |
| Chattopadhyay, A; Frey, S; Green, G | 1 |
| Casey, DE; Heisterberg, J; Sands, EE; Yang, HM | 1 |
| Wolf, W | 1 |
| Cussac, D; Depoortere, R; Newman-Tancredi, A | 1 |
| Forbes, RA; Kikuchi, T; Kitagawa, H; McQuade, RD; Stark, A; Tadori, Y | 1 |
3 review(s) available for benzoxazoles and Schizophrenia
| Article | Year |
|---|---|
Bifeprunox versus placebo for schizophrenia.
Topics: Antipsychotic Agents; Benzoxazoles; Drug Approval; Humans; Intention to Treat Analysis; Piperazines; Randomized Controlled Trials as Topic; Schizophrenia; Schizophrenic Psychology; United States; United States Food and Drug Administration | 2016 |
DU-127090 Solvay/H Lundbeck.
Topics: Antipsychotic Agents; Benzoxazoles; Biphenyl Compounds; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Dopamine Agonists; Humans; Piperazines; Receptors, Dopamine D2; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Schizophrenia; Serotonin Receptor Agonists | 2003 |
Neuropharmacological profile of bifeprunox: merits and limitations in comparison with other third-generation antipsychotics.
Topics: Animals; Antipsychotic Agents; Benzoxazoles; Cognition Disorders; Drug Design; Drug Resistance; Humans; Molecular Structure; Neuropharmacology; Piperazines; Schizophrenia | 2007 |
1 trial(s) available for benzoxazoles and Schizophrenia
| Article | Year |
|---|---|
Efficacy and safety of bifeprunox in patients with an acute exacerbation of schizophrenia: results from a randomized, double-blind, placebo-controlled, multicenter, dose-finding study.
Topics: Acute Disease; Adult; Antipsychotic Agents; Benzoxazoles; Body Weight; Cholesterol; Dose-Response Relationship, Drug; Double-Blind Method; Dyskinesia, Drug-Induced; Electrocardiography; Female; Gastrointestinal Diseases; Humans; Male; Middle Aged; Neurologic Examination; Piperazines; Prolactin; Psychiatric Status Rating Scales; Risperidone; Schizophrenia; Treatment Outcome; Triglycerides | 2008 |
3 other study(ies) available for benzoxazoles and Schizophrenia
| Article | Year |
|---|---|
Bifeprunox vs Placebo for Schizophrenia.
Topics: Antipsychotic Agents; Benzoxazoles; Humans; Piperazines; Schizophrenia | 2016 |
Molecule of the month. Bifeprunox mesilate.
Topics: Antipsychotic Agents; Benzoxazoles; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Humans; Piperazines; Schizophrenia | 2005 |
Differences in agonist/antagonist properties at human dopamine D(2) receptors between aripiprazole, bifeprunox and SDZ 208-912.
Topics: Animals; Aripiprazole; Benzoxazoles; CHO Cells; Cricetinae; Cricetulus; Cyclic AMP; Dopamine Agonists; Dopamine Antagonists; Dose-Response Relationship, Drug; Ergolines; Humans; Piperazines; Quinolones; Radioligand Assay; Receptors, Dopamine D2; Schizophrenia | 2007 |